|

Zanidatamab Clinical Trials

12 actively recruiting trials across 6 locations

Also known as: JZP598, ZIIHERA®, ZW25, Ziihera, zani

Other4 trials

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
Phase 2
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Phase 2
Personalized Medicine for Advanced Biliary Cancer Patients
Phase 3
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
Phase 2

Birmingham, Alabama2 trials

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of Alabama at Birmingham

Phase 2
PRE-I-SPY Phase I/Ib Oncology Platform Program

The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center

Phase 1

Phoenix, Arizona2 trials

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Mayo Clinic Scottsdale - PPDS

Phase 3
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Mayo Clinic-Arizona

Phase 1/2

Prescott, Arizona1 trial

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Arizona Oncology Associates, PC - NAHOA

Phase 2

Duarte, California1 trial

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

City of Hope(City of Hope National Medical Center, City of Hope Medical Center)

Phase 3

Long Beach, California1 trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Oncology Institute

Phase 2

Houston, Texas1 trial

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.